Literature DB >> 24661819

The relevance of living supports on antiplatelet adherence and trial participation: the SPS3 trial.

Brandy L Lewis1, Lesly A Pearce, Thalia S Field, Carole L White, Oscar R Benavente.   

Abstract

BACKGROUND: While living with others has been associated with improved functional outcome after acute stroke, it is unclear if this affects adherence to stroke prevention measures. AIMS: We examined the relationship between living arrangements and adherence to antiplatelet therapy assignment and participation status in an international randomized trial for secondary stroke prevention.
METHOD: Antiplatelet therapy adherence, trial retention outcomes, and baseline characteristics for participants enrolled in the Secondary Prevention of Small Subcortical Strokes study were compared between those who lived alone vs. with others (n = 2374). Participant status at end-of-trial was categorized into (1) on assigned antiplatelet, (2) off assigned antiplatelet by participant request, or (3) participant withdrew consent/lost to follow-up. Multivariable multivariate logistic regression was used to identify patient features at entry predictive of participant status at trial end.
RESULTS: Living arrangement, alone vs. with other(s), was not significantly associated with participant status. Participants enrolled in the United States/Canada (odds ratio 3.1, confidence intervals 2.0-5.0, vs. Latin America), taking more (7+) prescription medications (odds ratio 1.7, confidence intervals 1.1-2.7, vs. 0-2 medications), and scoring lower on the Stroke Specific Quality of Life scale (odds ratio 1.3, confidence intervals 1.1-1.5, per 10 points) were more likely to withdraw or become lost to follow-up in the study vs. completing the study on assigned antiplatelet therapy. Participants enrolled in the United States/Canada (odds ratio 5.0, confidence intervals 2.4-10.0, vs. Latin America) and taking fewer (0-2) medications (odds ratio 1.9, confidence intervals 1.2-3.1 vs. 3-6 medications) were more likely to request discontinuation of assigned antiplatelet medication vs. completing the study.
CONCLUSION: Living with others was not independently predictive of protocol adherence in this cohort. Number of medications and Stroke Specific Quality of Life scale score may be more indicative of likelihood of trial participation and acceptance of long-term antiplatelet regimen.
© 2014 The Authors. International Journal of Stroke © 2014 World Stroke Organization.

Entities:  

Keywords:  adherence; antiplatelet therapy; clinical trial; living support; retention; stroke

Mesh:

Substances:

Year:  2014        PMID: 24661819      PMCID: PMC4167670          DOI: 10.1111/ijs.12267

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  26 in total

Review 1.  Understanding and improving patient compliance.

Authors:  S A Eraker; J P Kirscht; M H Becker
Journal:  Ann Intern Med       Date:  1984-02       Impact factor: 25.391

Review 2.  Patient adherence to treatment: three decades of research. A comprehensive review.

Authors:  E Vermeire; H Hearnshaw; P Van Royen; J Denekens
Journal:  J Clin Pharm Ther       Date:  2001-10       Impact factor: 2.512

3.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

4.  Social support and patient adherence to medical treatment: a meta-analysis.

Authors:  M Robin DiMatteo
Journal:  Health Psychol       Date:  2004-03       Impact factor: 4.267

5.  The profile of recovery from stroke and factors influencing outcome.

Authors:  M Kotila; O Waltimo; M L Niemi; R Laaksonen; M Lempinen
Journal:  Stroke       Date:  1984 Nov-Dec       Impact factor: 7.914

6.  Pill count measures of compliance in a drug trial: variability and suitability.

Authors:  P Rudd; R L Byyny; V Zachary; M E LoVerde; W D Mitchell; C Titus; G Marshall
Journal:  Am J Hypertens       Date:  1988-07       Impact factor: 2.689

7.  Predicting functional outcome in acute stroke: comparison of a simple six variable model with other predictive systems and informal clinical prediction.

Authors:  C Counsell; M Dennis; M McDowall
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

8.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.

Authors:  O R Benavente; C S Coffey; R Conwit; R G Hart; L A McClure; L A Pearce; P E Pergola; J M Szychowski
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

9.  Quality of life after stroke. Impact of stroke type and lesion location.

Authors:  R J de Haan; M Limburg; J H Van der Meulen; H M Jacobs; N K Aaronson
Journal:  Stroke       Date:  1995-03       Impact factor: 7.914

10.  Social support, marital status and living arrangement correlates of cardiovascular disease risk factors in the elderly.

Authors:  M D Gliksman; R Lazarus; A Wilson; S R Leeder
Journal:  Soc Sci Med       Date:  1995-03       Impact factor: 4.634

View more
  1 in total

1.  Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Authors:  Tanzila Shams; Alexander P Auchus; Suzanne Oparil; Clinton B Wright; Jackson Wright; Anthony J Furlan; Cathy A Sila; Barry R Davis; Sara Pressel; Jose-Miguel Yamal; Paula T Einhorn; Alan J Lerner
Journal:  Stroke       Date:  2017-09-27       Impact factor: 7.914

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.